Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma

To evaluate the efficacy and safety of relmacabtagene autoleucel combined with autologous hematopoietic stem cell transplantation, orelabrutinib, and sintilimab as first-line or relapsed/refractory treatment for primary central nervous system diffuse large B-cell lymphoma.

NCT Number	NCT07198464
Lead Sponsor	Zhengzhou University
Conditions	Primary Central Nervous System Lymphoma (PCNSL)
Enrollment	30 participants
Start Date	2025-10-07
Primary Completion	2029-10-01 (estimated)
Study Completion	2029-10-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-30